课题基金 / 基金详情

GEMINI-OS : platform informatics for data-driven neuromodulation

GEMINI-OS : platform informatics for data-driven neuromodulation
GEMINI-OS:数据驱动神经调节的平台信息学
批准号:
10036282
负责人:
金额:
$232.23万
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
深部脑刺激(DBS)是一种治疗晚期帕金森病(PD)和震颤的有效方法,可以显著改善患者的生活质量。PD是一种进行性疾病,有对症治疗,但无法治愈。在晚期,药物可能无法控制症状,通常会引起运动和非运动相关的副作用。在这个阶段,PD患者可以被转介到DBS中心,在那里,包括神经学家和脑外科医生在内的专家团队在可能提供手术之前进行广泛的评估。虽然DBS可能是一种改变生活的治疗方法,但多达四分之一的患者未能从DBS中受益,有些患者甚至在手术后病情恶化。相反,一些本可以从中受益的病人却没有得到治疗。这种失败或无法获得治疗的主要原因是由于这种强大疗法的选择过程不正确。虽然在过去的20年里,设备的技术进步极大地改善了DBS治疗的提供,但选择最佳候选人的能力仍然保持不变。遴选过程基于30多年前确立的标准,主要依据个别中心的成果、经验和知识。因此,进行DBS手术的决定是基于对所有数据的人工临床评估,这依赖于不同中心每个团队的技能和经验,导致高度可变性。该项目将开发一种新的临床工具,以促进和改善DBS患者的选择。我们将开发一个新颖的平台,结合手术前后的数据来确定哪些因素可以预测手术的好结果或坏结果。为患者选择提供一个数据驱动的、客观的工具,将通过以下方式改善这一过程:1)减少手术后病情恶化的人数;2)增加接受治疗的人数,包括早期治疗的人数;3)使临床医生在选择过程中更有信心。该平台还将允许团队借鉴使用该平台的所有中心的经验,而不仅仅是他们自己的经验。目前,由于资格标准狭窄,英国只有500人符合临床资格,尽管更多的患者被认为可能受益。这个平台将给我们更大的信心,让更多的患者受益。
英文摘要
Deep Brain Stimulation (DBS) is an established treatment for advanced Parkinson's disease (PD) and tremor which may significantly improve their quality of life. PD is a progressive disease for which there are symptomatic treatments but no cure. In the advanced stages, medications can fail to control symptoms and commonly cause movement and non-movement related side effects. At this stage, people with PD can be referred to a DBS centre where a team of experts, including a neurologist and a brain surgeon, conduct extensive assessments before potentially offering surgery.While DBS can be a life-changing treatment, up to 1 in 4 patients fail to benefit from DBS and some even worsen following surgery. Conversely, some patients who would benefit from it are not offered treatment. The main reason for such failure or inaccessibility to treatment is due to the incorrect selection process for this powerful therapy. Whilst technological improvements in the devices have massively improved the delivery of DBS treatment over the last 20 years, the ability to select the best candidates has remained static.The selection process is based on criteria established more than 30 years ago and is largely informed by the outcomes, experience and knowledge by an individual centre. Thus, the decision to undertake DBS surgery is based on manual clinical evaluation of all the data which relies on the skills and experience of each individual team at the different centres, leading to high levels of variability.This project will develop a new clinical tool which will facilitate and improve patient selection for DBS. We will develop a novel platform that combines data from before and after surgery to determine what factors predict a good or poor outcome from surgery. Providing a data-driven, objective tool for patient selection, will improve the process by: 1) reducing the number of people who will deteriorate following surgery; 2) increasing the number of people who are offered treatment, including those in the earlier stages; 3) giving clinicians greater confidence in the selection process. This platform will also allow the teams to draw on the experience from all of the centres using the platform, rather than just their own. Currently, only 500 people in the UK meet the clinical eligibility due to the narrow eligibility criteria although many more patients are thought to potentially benefit. This platform would give greater confidence to widen access and allow more patients to benefit.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Lnc-Hnf4αos通过PPARα/γ轴介导氧化磷酸化诱导巨噬细胞极化加重HIRI的机制及应用研究
OSβG胶束‘2-in-1’荷载和控释脂溶性成分的时空机制研究
m6A甲基化修饰lncRNA-Fgf2os介导巨噬细胞M2极化参与视网膜新生血管形成
  • 批准号:
    2025JJ50628
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    周也荻
  • 依托单位:
LncRNA EMX2OS通过靶向miRNA-31/ TBXA2R轴抑制宫颈癌细胞的增殖,迁移和侵袭